Introduction
Studies in general practice have shown that depressive symptoms are a frequent and important problem (Fry, 1961; Watts, 1966; Shepherd et al., 1966) . During the 32 months of a survey about 1 in 13 women in a practice in Surrey attended at least once on account of a depressive illness (Porter, 1970) . Few of the patients who present to their general practitioner with depressive symptoms are referred to psychiatric outpatient clinics, and fewer still are admitted to hospital. Thus there are likely to be differences between general practice populations and hospital populations of depressives.
To date, two controlled trials of antidepressants have been reported from general practice (Porter, 1970; Rickels et al., 1970) . In the British study (Porter, 1970) (Rickels et al., 1970) amitriptyline was more effective than placebo. Most trials have been conducted on hospital populations and, in general, they have yielded conflicting results (Klerman and Cole, 1963; Leyburn, 1967) . In a review of the conflicting reports on the efficacy of antidepressants (Davies, 1968) it was pointed out that psychiatric opinions about the value of these drugs range from the optimistic view that "antidepressant drugs have revolutionized the treatment of depressed patients" to the cynical attitude that "antidepressants are only complex placebos for doctors."
Notwithstanding the conflicting evidence for their efficacy, the prescribing of antidepressants has steadily increased to the extent that between 1964 and 1966 the cost of antidepressants to the National Health Service rose from £2-37 to £3-13 million (Lancet, 1967) . As the bulk of these prescriptions were from general practitioners it would seem to be important to test the efficacy of antidepressants on depressed patients as they present in general practice.
The main practical problems that face the investigator in general practice are the establishment of an operational definition of "depression," the use of reliable measures of change, ensuring that patients included in the trial have taken the prescribed tablets, and the detection of side effects. In addition, different doses of the active drug should be studied and the drug should be given for a sufficient period of time.
Amitriptyline was selected because it is a frequently used antidepressant in general practice. A period of four weeks was chosen because of the reports that antidepressant effects may not be seen for three weeks. The aim was to use a practical but rigorous methodology to compare the value of amitriptyline at two dosage levels-the "general practice" level of 75 mg/day and the "hospital level" of 150 mg/day. To take into account the placebo effect, comparison with an inert substance was introduced, and other patients received amylobarbitone 150 mg/day. The design required four matched groups of patients attending their family doctors for treatment of their depressive illnesses. Particular attention was paid to socioeconomic factors-a decision which was subsequently justified by the finding that these factors interacted significantly with treatment effects (Rickels et al., 1970) .
In general, the conventional methods of hospital drug trials can be used in general practice. The effects of patients' expectations and physicians' enthusiasm can be reduced by using double-blind conditions. Standard techniques of assessment can be applied as readily to general practice as to hospital patients. Bias dug_r socioeconomic factors can be overcome by selecting patients from a number of practices. In one important respect, however, the general practice trial was considered to differ from the hospital trial. Most hospital trials do not select patients until they have been in hospital for 7 to 10 days, and any patients who improve in this time are usually excluded from the trial. Such a waiting period would be clinically unreal in general practice, and it was decided that a practical trial had to start from the patient's first presentation.
Patients and Methods
The patients studied were attending 21 general practitioners in Melbourne over a six-month period. The practices were deliberately selected to conform to eight socioeconomic areas of the city that have been described (F. L. Jones, 1967) . In view of the reported sex differences in incidence of depression (Porter, 1970) and in response to antidepressants (Hamilton, 1967 ) only females over 15 years were studied (mean age 37.7).
Rigorous clinical criteria for admission to the trial were established beforehand and were discussed in detail with each of the general practitioners involved. It was agreed that a patient should have a persistent lowered mood with depressive symptoms-sleep and appetite disturbances, loss of interest, and inability to concentrate-and that her mental state should show depression and anxiety. Other psychiatric syndromes-organic brain disorders, schizophrenia, epilepsy, alchoholism, and mental retardation-had to be absent. Further, no patient was admitted to the trial if she had had electric convulsion treatment in the previous three months or had received any antidepressant medication in the previous month.
Patients were selected by the general practitioner and were asked to return to the surgery on the following day to be seen for one hour by a psychiatrist (T.G.B.). The capsules were then given to the patient by her family doctor. Every effort was made to avoid biasing the circumstances of the trial away from those that would normally occur in the management of depressive illnesses in a general practice setting.
MEASURES OF DEPRESSION AND ANXIETY
In addition to the clinical examination a number of objective and subjective assessments were undertaken of depressive and anxiety symptoms.
The Hamilton (1960) Treatments Amitriptyline (Laroxyl) 25 and 50 mg, amylobarbitone 50 mg, and an inert substance were all prepared in identical orange capsules. Riboflavine 2.5 mg was added to each capsule so that at 7 and 28 days urine samples could be tested for riboflavine fluorescence (I. H. Jones, 1967) in order to detect patients who were not taking their capsules. Every general practitioner was given a number of coded bottles each containing a four-week supply of capsules. When he admitted a patient to the trial he noted the patient's name against the code on the label and instructed her to take one capsule three times a day. The code was kept separately so that both the general practitioner and the psychiatrist were blind as regards the contents of the capsules received by any patient. When the general practitioner thought a hypnotic was needed, nitrazepam (Mogadon) was supplied (5-10 mg at night). No other drugs were prescribed during the period of the trial. General practitioners were provided with an "escape clause" so that any patient who, in their opinion, became worse or complained of severe side effects could be removed from the trial.
Results
During the six months 82 patients were admitted to the trial but two were excluded by the psychiatrist (on day 1) as being too ill for general-practitioner treatment, and two failed to attend for the first psychiatric interview. A further 17 failed to complete the trial ("non completers") and are discussed later. Of the 61 patients who completed the trial, it was found that 18 had received the inert capsules, 16 had received amylobarbitone 50 mg three times a day, 13 had received amitriptyline 25 mg three times a day, and 14 had received amitriptyline 50 mg three times a day.
Analysis of data from the patients' records showed that no differences in composition occurred between any of the four treatment groups and the "non-completers" with regard to marital status, number of children, education, socioeconomic background, religion, and country of birth.
The differences in number in the treatment groups would appear to have arisen by chance, as no relationship was found between treatment allocated and failure to complete the trial. Of the 17 "non-completers" five were in fact in the inert group and four in each of the other treatment groups.
The mean scores and their standard deviations for each treatment group at the three assessments are shown in Table I. INITIAL RATINGS When Student's t test was applied to the initial scores no significant differences were found between mean ages and between mean scores on all measures for the four treatment groups, except for the patients on amylobarbitone, who were rated as significantly lower on the Hamilton scale than the group on inert treatment (r=2-1; P=0-05). With this exception, the groups were considered to be matched for age and severity of depression and anxiety at the beginning of the trial.
The BRITISH MEDICAL JOURNAL 16 JANUARY 1971 The findings in terms of the average number of side effects reported at the beginning of the trial are summarized in Table V . From this it is seen that a considerable number of symptoms were already present before the trial began. Some of these initial symptoms persisted during the trial (Table V) . "True" side effects were taken to be those which emerged only in the course of treatment, and their average numbers are given in Table V . No significant differences between the treatment groups were noted in the average numbers of side effects occurring during the trial. This analysis provides perspective and indicates the difficulty of identifying side effects of any drug. The eight side effects which appeared most frequentlythat is, in more than four out of the total groups-are listed in Table VI in the manner in which they were presented to the patients. "Shakiness of legs or arms" and "blurred vision" were reported in all treatment groups. "Dry mouth" was more common with amitriptyline, but was also reported by two patients on amylobarbitqne. "Fuzziness or unclearness in the head" was reported by all groups, except for amitriptyline 75 mg/day. "Pains in the stomach" appear to be related to amitriptyline alone. Of the less frequent side effects (not listed) which could be attributed to amitriptyline, "swelling of the legs" was reported by three of the amitriptyline 75 mg/day group only, "incoordination of legs or arms" by two of the amitriptyline 150 mg/day only, and "chest pain" by two of the amitriptyline 75 mg/day only. In fact, no obvious differences were observed between the number and nature of side effects at the two dosage levels of amitriptyline. Somewhat unexpectedly, "constipation" was not reported with either of the two levels of amitriptyline-the two patients in the whole group who reported this were on amylobarbitone.
"NON-COMPLETERS" Because they contributed a group comparable in size to the treatment groups it is important to consider in detail the 17 patients who failed to complete the trial. As mentioned previously, failure to complete was not related to the allocated treatment, and Table VII further shows that there the presence of such situational problems was noted and assessed clinically as "relevant" or "not relevant" to the clinical picture. At 7 and 28 days subsequent changes in the situation were noted. At the end of the trial 48 of the 61 patients were considered to have been subject to relevant situational factors. Testing by x2 showed that no significant differences occurred between the four treatment groups in the number of patients in whom the situational factors were considered to be relevant or not, and in the number in whom the relevant situational factors were considered to have improved, remained the same or worsened. Table IV relates the presence of relevant situational factors to the assessed outcome for the group as a whole at the end of the trial. No significant differences were found by x2 between the numbers "improved" or "not improved" showing "relevant" or "not relevant" situational factors, nor in the numbers in whom the situational factors improved, remained the same, or worsened.
SIDE EFFECTS
Patients recorded their experiences of side effects on the prepared list of 23 items, with space provided for any unlisted symptoms. This method was more convenient than simply noting any spontaneously reported complaints, but it involved the risk of suggesting side effects to the patients. As all patients used these lists, no bias toward any treatment group could operate. This recording was done at the beginning of the trial as well as at the two follow-up interviews. The 11 patients who failed to complete treatment because of side effects were distributed equally between the inert capsules and the two dosage levels of amitriptyline. For those on amitriptyline the two major reasons given were excessive drowsiness and a general slowing down of all activities. Nausea, drowsiness, dry mouth, and fuzziness of the head were reported by the patients on inert capsules. While none reported side effects three patients on amylobarbitone stopped taking the capsules because they felt they had become more depressed.
All of these 14 patients stopped taking the tablets within the first week of the trial. Twelve admitted spontaneously that they had stopped taking the capsules. The other two did not admit to having stopped, but urine tests showed no evidence of riboflavine fluorescence. These were the only cases in which failure to take the capsules was detected. All the 61 patients who completed the trial had positive tests for riboflavine in their urine at days 7 and 28.
Discussion
Multiple measures of change in the patients provided a wide coverage of both observer rating and self-assessment of depressive and anxiety features. There was an overall agreement in the trends yielded by these measures (see Chart), but there were obvious differences (see Tables II and  III) in the degree to which the changes reached statistical significance. In general the observer ratings tended to be more likely to yield significance than the self-assessments. The problem then arises of whether to place more weight on the doctor's ratings and judgements or the patient's own assessment.
The rating scale method is relatively new and so far no specific information is available on the intercorrelations between these measures and their relative sensitivity to change. On general groundsy Hamilton (1960) argues that because the patient is inexperienced or unsophisticated in filling in inventories of this kind, the reliability of assessment methods is likely to be lower than the ratings of the experienced clinician. Rickels et al. (1970) emphasize the sensitivity of the Zung self-rating scale to population effects and its lack of sensitivity to drug effects when compared with objective ratings of depression. On these grounds the greater weight was placed on the objective measures.
As a group the patients who completed the trial all showed some improvement in their depression irrespective of which treatment 'was allocated. It is of interest to note that after 7 days 55%, and at 28 days 61%, of the patients on the inert substance were considered to have improved on clinical grounds. This represents a higher rate of improvement than occurs with inert tablets in psychiatric outpatients and inpatients (Rickels et al., 1970 No differences between imipramine and placebo were found, leading to the conclusion that depression in general practice may be effectively treated with support and a placebo. The findings of the present study would suggest that at the level of 150 mg/day amitriptyline has effects over and above the placebo effect. Rickels et al. (1970) found that amitriptyline at a dosage of 100 mg/day was superior to placebo over a fourweek period.
Comparative trials of imipramine and amitriptyline have produced conflicting results (Klerman and Cole, 1963) . The different results which have been reported are most likely due to differences in the patients selected for the trials, to lack of uniformity in the dosage and length of administration of the antidepressants, as well as to differences in the methods used to assess changes in the patient's condition.
The effects of the medications on anxiety symptoms are of interest. All treatments, except the inert substance, produced a significant reduction in anxiety scores, which paralleled the reduction in depressive scores. After 28 days amitriptyline 150 mg/day was significantly better than the other treatments. Amylobarbitone was superior to the inert tablets at seven days in reducing anxiety scores, but this superiority did not persist to 28 days, when amylobarbitone, inert treatment, and amitriptyline 75 mg/day could not be separated. The advantages of amitriptyline 150 mg over amylobarbitone 150 mg/day could not be demonstrated to a statistically significant degree. This raises the question of whether "sedative" or "antidepressant properties" are being measured. In general the tendency was for amylobarbitone 150 mg/day to achieve its improvement in the first seven days only, whereas improvement with amitriptyline 150 mg/day continued over the period of the trial. This continued improvement may be consistent with so-called antidepressant effects. Analysis of the Hamilton ratings in terms of Hamilton's depression and anxiety factors, however, showed that while both amylobarbitone 150 mg/day and amitriptyline 150 mg/day produced improvement on these two factors, the improvement with amitriptyline was significantly greater. A more specific study would be required to test whether antidepressant and sedative effects could be separated and would require variation in the dosage of amylobarbitone administered.
The group of patients who did not complete the trial could not be identified on the basis of their background data or on the measures made at the beginning of the trial. The proportion of "non-completers" to those admitted to the trial agrees with that found in Porter's study (19/93 JANUARY 1971 anxiety and depressive symptoms, and (4) depressed patients who stop medication complaining of side effects do not necessarily do so because these are pharmacologically induced.
